Addison’s Disease Market to Grow with a CAGR of 6.51% through 2028
Expansion of
pharmaceutical innovations and treatment options is expected to drive Global Addison’s
Disease Market growth in the forecast period, 2024-2028.
According
to TechSci Research report, “Addison’s Disease Market – Global Industry
Size, Share, Trends, Competition Forecast & Opportunities, 2028”,
the Global Addison’s Disease Market stood at USD 401.12 Million in 2022 and is
anticipated to grow with a CAGR of 6.51% in the forecast period, 2024-2028. Addison's
Disease, also known as primary adrenal insufficiency, is a rare but
life-altering endocrine disorder characterized by the inadequate production of
cortisol and aldosterone hormones by the adrenal glands. This condition requires
lifelong management and treatment, and recent advancements in research,
diagnostics, and therapeutics have played a pivotal role in boosting the market.
One of the primary drivers behind the growth of the Addison's Disease market is
the increasing awareness of the condition among both healthcare professionals
and the general population. As awareness spreads, more individuals with
symptoms indicative of adrenal insufficiency are being correctly diagnosed at
an earlier stage. Early diagnosis is crucial for preventing life-threatening
adrenal crises and improving overall patient outcomes. Efforts from advocacy
groups, patient organizations, and healthcare providers have contributed to
this heightened awareness. Moreover, educational initiatives and awareness
campaigns have made a significant impact, ensuring that healthcare
professionals are more likely to consider Addison's Disease when evaluating
patients with relevant symptoms such as fatigue, weakness, weight loss, and low
blood pressure.
Advancements in
diagnostic technologies have played a pivotal role in boosting the Addison's
Disease market. The development of more accurate and efficient diagnostic tests
has made it easier to confirm the presence of adrenal insufficiency, allowing
for prompt initiation of treatment. Key diagnostic tools include the ACTH
stimulation test, cortisol and aldosterone blood tests, and imaging studies
like CT scans and MRI to assess the adrenal glands. In recent years, there has
been a growing emphasis on the development of more sensitive and specific
diagnostic assays, enabling earlier detection and differentiation from other
similar conditions. Pharmaceutical companies have been at the forefront of
innovation in the Addison's Disease market. Corticosteroid medications, which
are essential for hormone replacement therapy, have seen significant
improvements in terms of formulation, dosage options, and administration
methods. These innovations are aimed at providing patients with more precise
and individualized treatment regimens. Slow-release formulations and
implantable devices have been introduced to reduce the frequency of medication
administration and minimize the risk of hormonal imbalances. These developments
enhance patient adherence to treatment plans and improve overall disease
management.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on
"Global Addison’s Disease Market”
Access to
Addison's Disease medications and treatments has expanded to previously
underserved regions, contributing to the growth of the global market.
Regulatory approvals for medications and treatment options have been achieved
in various countries, allowing a broader patient population to benefit from
these advancements. Global collaborations between pharmaceutical companies and
healthcare organizations have facilitated the distribution of essential
medications to regions where Addison's Disease was previously underdiagnosed or
undertreated. This expansion of geographic reach is a critical driver in
increasing the number of patients receiving appropriate care and management.
The Global Addison’s
Disease Market is segmented into type, drug class, distribution channel,
regional distribution, and company.
Based on type,
the Global Addison’s Disease Market is segmented into Primary
Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal
Insufficiency. Based on the type, the Primary Adrenal Insufficiency segment
emerged as the dominant segment in the global market for Global Addison’s
Disease Market in 2022. Primary Adrenal Insufficiency, synonymous with
Addison's Disease, is the most common type addressed in medications and
treatments because it directly relates to the malfunction of the adrenal
glands, which are the key players in the production of cortisol and
aldosterone. Addison's Disease is the most
common form of adrenal insufficiency. While secondary and tertiary adrenal
insufficiency can occur due to pituitary or hypothalamic issues, Addison's
Disease is the predominant form of adrenal insufficiency, accounting for the
majority of cases. This high prevalence naturally makes it the primary focus
for research, treatment development, and clinical practice.
Based on Drug
Class, the Global Addison’s Disease Market is segmented into Oral Corticosteroid, Corticosteroid Injections, Sodium
Intake. Based on the Drug Class, the oral corticosteroids segment emerged as
the dominant player in the global market for Global Addison’s Disease Market in
2022. Oral corticosteroids are the most
widely utilized drug class in the treatment of Addison's Disease due to their
convenience, availability, flexibility in dosing, and suitability for long-term
management. Oral corticosteroids are readily
available in various formulations, including tablets and capsules, allowing
healthcare providers to tailor the dosage to individual patient needs. The
consistency in drug availability and dosage options ensures that patients
receive the appropriate amount of cortisol replacement therapy. The dosing of oral corticosteroids can be adjusted to
match the patient's specific requirements. Oral
corticosteroids facilitate close monitoring and titration of hormone
replacement therapy.
North America
emerged as the dominant player in the global Addison’s Disease Market in 2022, holding the largest market share. The
region has been a hub for research and development (R&D) activities in the
field of Addison's Disease. Pharmaceutical companies and research institutions
in North America have been actively engaged in developing innovative treatment
options, including advancements in hormone replacement therapy and potential
genetic therapies. North America has
easy access to advanced diagnostic technologies, which have greatly improved
the accuracy and efficiency of Addison's Disease diagnosis. These technologies
include highly sensitive assays, imaging studies, and genetic testing, enabling
healthcare providers to identify and manage the condition more effectively.
Major companies
operating in Global Addison’s Disease Market are:
- Teva Pharmaceuticals
- Ralington Pharma
- Aspen Pharma
- Pfizer Inc
- Merck KGA
- Anant Pharmaceuticals
- Symbiotech
- Curia
- AuroPharma
- Parchem Fine & Specialty Chemicals
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“The
global Addison's Disease market is poised for significant growth in the coming
years, driven by several key factors. Firstly, increasing awareness and
improved diagnostic capabilities are expected to lead to a higher rate of early
disease detection, allowing for prompt initiation of hormone replacement
therapy. Secondly, ongoing research and development efforts in the field of
Addison's Disease are paving the way for innovative treatment modalities. From
refinements in corticosteroid formulations to the exploration of gene therapy
and regenerative medicine, these advancements hold promise for more effective
and personalized treatment options. Besides, the expansion of pharmaceutical innovations
and treatment options will contribute to market growth. As pharmaceutical
companies continue to invest in Addison's Disease research, patients can
anticipate improved medication formulations and delivery systems, reducing the
complexity of hormone replacement therapy.” said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based management consulting firm.
“Addison’s
Disease Market - Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type (Primary
Adrenal Insufficiency, Secondary Adrenal Insufficiency, Tertiary Adrenal
Insufficiency), By Drug Class (Oral Corticosteroid, Corticosteroid Injections,
Sodium Intake), By Distribution Channel (Hospital Pharmacies, Retail
Pharmacies, Online Pharmacies) By Region and Competition”,
has evaluated the future growth potential of Global Addison’s Disease Market and
provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Addison’s Disease Market.
Contact
Mr. Ken Mathews
708 Third
Avenue,
Manhattan, NY,
New York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com